Please assess the completion status of the following clinical trial:

Trial Title: PTX-200 and Carboplatin in Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Histologically confirmed, measurable or non-measurable, recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma. By standard Gynecologic Oncology Group (GOG) criteria, platinum-resistant disease is defined by a disease-free interval of less than 6 months following treatment with a platinum-based regimen, or the progression of disease during platinum-based therapy.~* At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles~* A serum creatinine ≤ 1.5 mg% obtained ≤ 2 weeks prior to entry~* Adequate hematologic reserve obtained ≤ 2 weeks prior to entry: leukocytes ≥ 3,000 mm\^3; absolute neutrophil count ≥ 1500 mm\^3; platelets ≥ 100,000 mm\^3~* Adequate hepatocellular function: aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 3x upper limit of normal within institutional limits; bilirubin ≤ 1.5 mg/dl~* Gynecologic Oncology Group (GOG) Performance Status of 0, 1, or 2~* Life expectancy of at least 90 days~* The patient should be off chemotherapy, biologic therapy and radiation for 28 days.~* Neuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity Criteria (CTC) version 4~Exclusion Criteria:~* Prior TCN-PM therapy~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PM~* Patients must be disease-free of prior invasive malignancies for \>2 years with the exception of basal cell or squamous cell carcinoma of the skin.~* Inability to give informed consent~* Pregnancy~* Corrected QT interval (QTc) prolongation \> 450 milliseconds (msec)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triciribine & Carboplatin (Type: EXPERIMENTAL): Phase I/II: 25mg/m\^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m\^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).